Patents by Inventor Nobuo Kubota
Nobuo Kubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11400076Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.Type: GrantFiled: October 2, 2018Date of Patent: August 2, 2022Assignees: KEIO UNIVERSITY, Sun Pharma Japan LimitedInventors: Hideyuki Saya, Oltea Sampetrean, Naoyoshi Koike, Nobuo Kubota
-
Patent number: 11090234Abstract: Provided is a product exhibiting good bubbles even from a screen foamer composition using a non-ionic surfactant. This foam contains a non-ionic surfactant and is composed of an air layer and a bubble shell encapsulating the air layer. The bubble shell has a high light transmission region which is optically transparent and a low light transmission region which is less optically transparent than the highlight transmission region, both regions being disposed so as to spread across a surface of the bubble shell in such a manner as to form an identifiable boundary therebetween; and when the foam is allowed to stand at 25° C., an area of the low light transmission region occupying the surface area of the bubble shell expands over time, and thus the entire surface of the bubble shell becomes occupied by the low light transmission region.Type: GrantFiled: June 9, 2017Date of Patent: August 17, 2021Assignee: POLA PHARMA INC.Inventors: Hirokazu Kobayashi, Takaaki Masuda, Nobuo Kubota, Kahori Fujii
-
Publication number: 20200316027Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.Type: ApplicationFiled: October 2, 2018Publication date: October 8, 2020Applicant: KEIO UNIVERSITYInventors: Hideyuki SAYA, Oltea SAMPETREAN, Naoyoshi KOIKE, Nobuo KUBOTA
-
Publication number: 20190133894Abstract: Provided is a product exhibiting good bubbles even from a screen foamer composition using a non-ionic surfactant. This foam contains a non-ionic surfactant and is composed of an air layer and a bubble shell encapsulating the air layer. The bubble shell has a high light transmission region which is optically transparent and a low light transmission region which is less optically transparent than the highlight transmission region, both regions being disposed so as to spread across a surface of the bubble shell in such a manner as to form an identifiable boundary therebetween; and when the foam is allowed to stand at 25° C., an area of the low light transmission region occupying the surface area of the bubble shell expands over time, and thus the entire surface of the bubble shell becomes occupied by the low light transmission region.Type: ApplicationFiled: June 9, 2017Publication date: May 9, 2019Inventors: Hirokazu KOBAYASHI, Takaaki MASUDA, Nobuo KUBOTA, Kahori FUJII
-
Patent number: 10130610Abstract: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C.Type: GrantFiled: April 9, 2010Date of Patent: November 20, 2018Assignees: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.Inventors: Hirokazu Kobayashi, Eiko Kosugi, Nobuo Kubota
-
Patent number: 9491933Abstract: The invention can produce an infected nail of an animal and an infected animal model in which the nail plate and nail bed of the nail are sufficiently infected with a superficial fungus which were difficult to be produced in the past, and provides an evaluation method useful for development of a therapeutic agent for intractable infectious diseases such as tinea unguium using the nail and the infected animal model. For producing the infected nail of an animal and the infected animal model infected with a superficial fungus, an immunosuppressive component is administered to an animal in advance to decrease immunocompetence, and then, a superficial fungus is inoculated into the animal, whereby the infected nail of an animal and the infected animal model reflecting clinical manifestation in which the nail plate and nail bed of the nail are sufficiently infected with the superficial fungus can be produced with good reproducibility in a short period of time.Type: GrantFiled: December 25, 2008Date of Patent: November 15, 2016Assignee: POLA PHARMA, INC.Inventors: Nobuo Kubota, Tsuyoshi Shimamura, Saori Nagasaka
-
Patent number: 9050271Abstract: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C.Type: GrantFiled: April 9, 2010Date of Patent: June 9, 2015Assignees: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.Inventors: Hirokazu Kobayashi, Eiko Kosugi, Nobuo Kubota
-
Patent number: 8962669Abstract: An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R1, R2 independently represent hydrogen atom or halogen atom respectively, and at least one of R1, R2 is halogen atom.Type: GrantFiled: June 10, 2011Date of Patent: February 24, 2015Assignees: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.Inventors: Nobuo Kubota, Hirokazu Kobayashi, Takaaki Masuda
-
Patent number: 8952044Abstract: A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1?R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.Type: GrantFiled: July 29, 2010Date of Patent: February 10, 2015Assignees: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.Inventors: Hirokazu Kobayashi, Nobuo Kubota
-
Patent number: 8541459Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.Type: GrantFiled: January 17, 2008Date of Patent: September 24, 2013Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Patent number: 8450356Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.Type: GrantFiled: January 31, 2012Date of Patent: May 28, 2013Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Patent number: 8420687Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.Type: GrantFiled: January 31, 2012Date of Patent: April 16, 2013Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Publication number: 20130090365Abstract: An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R1, R2 independently represent hydrogen atom or halogen atom respectively, and at least one of R1, R2 is halogen atom.Type: ApplicationFiled: June 10, 2011Publication date: April 11, 2013Applicants: NIHON NOHYAKU CO., LTD., POLA PHARMA INC.Inventors: Nobuo Kubota, Hirokazu Kobayashi, Takaaki Masuda
-
Publication number: 20130011351Abstract: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C.Type: ApplicationFiled: April 9, 2010Publication date: January 10, 2013Applicants: Pola Pharma Inc., Nihon Nohyaku Co., Ltd.Inventors: Hirokazu Kobayashi, Eiko Kosugi, Nobuo Kubota
-
Patent number: 8268876Abstract: Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) ?-hydroxycarboxylic acid and/or a salt thereof.Type: GrantFiled: October 2, 2006Date of Patent: September 18, 2012Assignees: Nihon Nohyaku Co., Ltd., Pola Pharma Inc.Inventors: Toyohiko Miki, Akira Nozawa, Nobuo Kubota, Susumu Tomiyama, Hirokazu Kobayashi
-
Patent number: 8258166Abstract: A Cancer radiotherapeutic method using 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole (compound (i), and creatinine in an amount of 0.001 to part by mass with respect to 1 part by mass of compound (1); and irradiation.Type: GrantFiled: February 3, 2012Date of Patent: September 4, 2012Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Patent number: 8258165Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.Type: GrantFiled: April 16, 2008Date of Patent: September 4, 2012Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Patent number: 8202898Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.Type: GrantFiled: February 3, 2012Date of Patent: June 19, 2012Assignee: Pola Pharma Inc.Inventors: Yasushi Murakami, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota
-
Publication number: 20120149745Abstract: A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1?R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.Type: ApplicationFiled: July 29, 2010Publication date: June 14, 2012Applicants: NIHON NOHYAKU CO., LTD., POLA PHARMA INC.Inventors: Hirokazu Kobayashi, Nobuo Kubota
-
Publication number: 20120136295Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.Type: ApplicationFiled: February 3, 2012Publication date: May 31, 2012Applicant: POLA PHARMA INC.Inventors: Yasushi MURAKAMI, Naoko Kobayashi, Azuma Nishio, Nobuo Kubota